Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 8/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305652 | 1.00 | CASR (0.59) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL8285877 | 1.00 | CASR (0.59) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL410129 | 1.00 | CASR (0.59) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL19286306 | 0.85 | CASR (0.59) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL7862921 | 0.85 | CASR (0.59) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL12870263 | 0.83 | CASR (0.58) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL14438388 | 0.83 | CASR (0.58) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL7903255 | 0.83 | CASR (0.58) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL28508849 | 0.83 | CASR (0.58) | CASRPOLBCYP2D6AOC3MEN1 | |
| SCHEMBL13740795 | 0.83 | CASR (0.58) | CASRPOLBCYP2D6AOC3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-8420846-B2 | Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates | JUBILANT LIFE SCIENCES LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-2349976-B1 | A PROCESS FOR PRODUCING (S)-3-[(1-DIMETHYLAMINO)ETHYL]PHENYL-N-ETHYL-N-METHYL-CARBAMATE VIA NOVEL INTERMEDIATES | JUBILANT LIFE SCIENCES LTD (IN) | 2012-12-26 | — | — | EP | disclosed |
| EP-1939172-B1 | METHOD OF OBTAINING PHENYL CARBAMATES | INTERQUIM SA (ES) | 2012-07-11 | — | — | EP | disclosed |
| EP-1939172-B1 | METHOD OF OBTAINING PHENYL CARBAMATES | INTERQUIM SA (ES) | 2012-07-11 | — | — | EP | disclosed |
| US-20120022281-A1 | PROCESS FOR PRODUCING (S)-3-[(1-DIMETHYLAMINO)ETHYL] PHENYL-N-ETHYL-N-METHYL-CARBAMATE VIA NOVEL INTERMEDIATES | JUBILANT LIFE SCIENCES LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| EP-1939172-A2 | METHOD OF OBTAINING PHENYL CARBAMATES | Interquim, S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939172-A2 | METHOD OF OBTAINING PHENYL CARBAMATES | Interquim, S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007014973-A2 | METHOD OF OBTAINING PHENYL CARBAMATES | INTERQUIM, S.A. (ES) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | CASR 1039/4885POLB 3485/4885CYP2D6 3285/4885 |
| US-20120022281-A1 | PROCESS FOR PRODUCING (S)-3-[(1-DIMETHYLAMINO)ETHYL] PHENYL-N-ETHYL-N-METHYL-CARBAMATE VIA NOVEL INTERMEDIATES | ACHE, NNMT, BCHE | CASR 3204/4885POLB 3561/4885CYP2D6 423/4885 |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | CASR 3686/4885POLB 1938/4885CYP2D6 3376/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | CASR 381/4885POLB 4086/4885CYP2D6 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.